# A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

> **NCT03381196** · PHASE3 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 553 (actual)

## Conditions studied

- Influenza A

## Interventions

- **DRUG:** Pimodivir 600 mg
- **DRUG:** Placebo
- **OTHER:** SOC Treatment

## Key facts

- **NCT ID:** NCT03381196
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-01-21
- **Primary completion:** 2020-05-28
- **Final completion:** 2020-08-24
- **Target enrollment:** 553 (ACTUAL)
- **Why stopped:** Based on interim Analysis outcome being futile for FLZ3001; decision was taken to stop (early terminate) both FLZ3001/3002. There was no safety concern.
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03381196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03381196, "A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03381196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*